Literature DB >> 17544352

Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats.

R K Fuchs1, M Shea, S L Durski, K M Winters-Stone, J Widrick, C M Snow.   

Abstract

Exercise and bisphosphonate therapies increase bone strength by primarily increasing bone formation and reducing resorption, respectively. Based on these different mechanisms of action, it is possible that combined introduction of exercise and bisphosphonate therapies generates greater improvements in bone mass and strength than either intervention alone. The aim of this study was to examine the individual and combined effects of exercise (treadmill running) and bisphosphonate therapy (alendronate [ALN]) on bone mass and strength in ovariectomized (OVX) rats. Seven-month-old virgin female rats were randomly assigned to either a sham-OVX group (n=13) or one of four OVX groups: vehicle-treated cage-control (VEH-CON, n=10); ALN-treated cage-control (ALN-CON, n=13); vehicle-treated plus treadmill running (VEH-RUN, n=13); and ALN-treated plus treadmill running (ALN-RUN, n=13). ALN-treated groups received twice-weekly ALN (0.015 mg/kg), and exercise groups ran on a motorized treadmill at a 5% incline for 60 min/day, 22-24 m/min, 5 days/week. In vivo measurements included dual-energy X-ray absorptiometry (DXA) of whole-body bone mineral content (BMC), and ex vivo measurements included DXA, micro-computed tomography (muCT), and mechanical testing of the femur and L4 vertebrae. After 14 weeks of intervention, exercise and ALN had additive benefits on whole body and proximal femur BMC, cross-sectional area of the L4 vertebrae, and mechanical properties of the mid-shaft femur. In comparison, for total and mid-shaft femur BMC, L4 vertebrae BMC, and mid-shaft femur cortical thickness and area, there were significant exercise and ALN interactions indicating that the two interventions worked in synergy to enhance bone properties. Supporting the contention that ALN and exercise function via distinct mechanisms of action, ALN successfully reduced medullary canal area suggesting it reduced endocortical bone resorption, whereas exercise augmented periosteal perimeter suggesting it stimulated periosteal bone formation. In summary, we found combined treadmill running and ALN to be more beneficial in preventing declines in bone mass and strength following OVX than the introduction of either intervention alone. These data suggest that a comprehensive program of bisphosphonate therapy and weight-bearing exercise may be an effective method for preventing and treating osteoporosis in post-menopausal women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544352     DOI: 10.1016/j.bone.2007.04.179

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  19 in total

1.  Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.

Authors:  R D Chapurlat; M Laroche; T Thomas; S Rouanet; P D Delmas; M-C de Vernejoul
Journal:  Osteoporos Int       Date:  2012-03-09       Impact factor: 4.507

2.  Accuracy of trabecular structure by HR-pQCT compared to gold standard μCT in the radius and tibia of patients with osteoporosis and long-term bisphosphonate therapy.

Authors:  M Krause; O Museyko; S Breer; B Wulff; C Duckstein; E Vettorazzi; C Glueer; K Püschel; K Engelke; M Amling
Journal:  Osteoporos Int       Date:  2014-02-25       Impact factor: 4.507

3.  Alendronate does not prevent long bone fragility in an inactive rat model.

Authors:  K Naruse; K Uchida; M Suto; K Miyagawa; A Kawata; K Urabe; M Takaso; M Itoman; Y Mikuni-Takagaki
Journal:  J Bone Miner Metab       Date:  2015-10-16       Impact factor: 2.626

4.  Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.

Authors:  J Ignacio Aguirre; Mohammed P Akhter; Donald B Kimmel; Jennifer E Pingel; Alyssa Williams; Marda Jorgensen; Lakshmyya Kesavalu; Thomas J Wronski
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

5.  Finite-element analysis of the mouse proximal ulna in response to elbow loading.

Authors:  Feifei Jiang; Aydin Jalali; Chie Deguchi; Andy Chen; Shengzhi Liu; Rika Kondo; Kazumasa Minami; Takashi Horiuchi; Bai-Yan Li; Alexander G Robling; Jie Chen; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2018-07-30       Impact factor: 2.626

6.  Functional electrical stimulation (FES)-assisted rowing combined with zoledronic acid, but not alone, preserves distal femur strength and stiffness in people with chronic spinal cord injury.

Authors:  Y Fang; L R Morse; N Nguyen; R A Battaglino; R F Goldstein; K L Troy
Journal:  Osteoporos Int       Date:  2020-09-04       Impact factor: 4.507

7.  Ibuprofen before Exercise Does Not Prevent Cortical Bone Adaptations to Training.

Authors:  Vanessa D Sherk; R Dana Carpenter; Erin D Giles; Janine A Higgins; Robera M Oljira; Ginger C Johnson; Samuel Mills; Paul S Maclean
Journal:  Med Sci Sports Exerc       Date:  2017-05       Impact factor: 5.411

8.  Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.

Authors:  K Hatori; G V Camargos; M Chatterjee; F Faot; K Sasaki; J Duyck; K Vandamme
Journal:  Osteoporos Int       Date:  2014-09-19       Impact factor: 4.507

9.  Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.

Authors:  Nicolau Conte Neto; Luis C Spolidorio; Cleverton R Andrade; Alliny S Bastos; Morgana Guimarães; Elcio Marcantonio
Journal:  Int J Exp Pathol       Date:  2013-02       Impact factor: 1.925

10.  Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.

Authors:  Sarah K Amugongo; Wei Yao; Junjing Jia; Weiwei Dai; Yu-An E Lay; Li Jiang; Danielle Harvey; Elizabeth A Zimmermann; Eric Schaible; Neil Dave; Robert O Ritchie; Donald B Kimmel; Nancy E Lane
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.